NASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis $1.21 +0.12 (+11.01%) As of 01/8/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Context Therapeutics Stock (NASDAQ:CNTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Context Therapeutics alerts:Sign Up Key Stats Today's Range$1.08▼$1.2550-Day Range$0.98▼$2.2752-Week Range$0.89▼$2.75Volume783,242 shsAverage Volume342,874 shsMarket Capitalization$90.75 millionP/E RatioN/ADividend YieldN/APrice Target$6.33Consensus RatingBuy Company OverviewContext Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Read More… Context Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks50th Percentile Overall ScoreCNTX MarketRank™: Context Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 646th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingContext Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContext Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Context Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Context Therapeutics are expected to grow in the coming year, from ($0.51) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.67% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Context Therapeutics has recently increased by 22.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.67% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Context Therapeutics has recently increased by 22.86%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.17 News SentimentContext Therapeutics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.98 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Context Therapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for CNTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.04% of the stock of Context Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.03% of the stock of Context Therapeutics is held by institutions.Read more about Context Therapeutics' insider trading history. Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Stock News HeadlinesJMP Securities Initiates Coverage of Context Therapeutics (CNTX) with Market Outperform RecommendationJanuary 9 at 1:39 PM | msn.comInnovative Growth Potential: Silvan Tuerkcan’s Buy Rating on Context TherapeuticsJanuary 8 at 6:24 PM | markets.businessinsider.comCombine the QQQ, IWM and SPY in one tradeIf you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses… I want to tell you about my “2-Click Trade” that has encapsulated more than the return of ALL THREE OF THOSE INDEXES COMBINED… Plus, it targets multiple overnight payouts in a month with 84.3% accuracy! While I cannot promise future returns or against losses…January 9, 2025 | Diversified Trading Institute (Ad)Context Therapeutics (NASDAQ: CNTX)January 7 at 4:51 PM | fool.comContext Therapeutics Secures Funding for Cancer Therapy PipelineDecember 2, 2024 | markets.businessinsider.comD. Boral Capital Initiates Coverage of Context Therapeutics (CNTX) with Buy RecommendationNovember 26, 2024 | msn.comContext Therapeutics: Strategic Developments and Financial OutlookNovember 22, 2024 | markets.businessinsider.comPromising Preclinical Data and Strategic Trial Design Support Buy Rating for Context TherapeuticsNovember 12, 2024 | markets.businessinsider.comSee More Headlines CNTX Stock Analysis - Frequently Asked Questions How have CNTX shares performed this year? Context Therapeutics' stock was trading at $1.05 on January 1st, 2025. Since then, CNTX shares have increased by 15.2% and is now trading at $1.21. View the best growth stocks for 2025 here. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) announced its earnings results on Wednesday, November, 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.11. When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an initial public offering on Wednesday, October 20th 2021. The company issued 5,000,000 shares at $5.00 per share. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Context Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS). Company Calendar Last Earnings11/06/2024Today1/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTX CUSIPN/A CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$6.33 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+423.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.76% Return on Assets-55.80% Debt Debt-to-Equity RatioN/A Current Ratio36.91 Quick Ratio36.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book1.64Miscellaneous Outstanding Shares74,998,000Free Float72,718,000Market Cap$90.75 million OptionableNot Optionable Beta2.10 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:CNTX) was last updated on 1/9/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.